延迟释放缩径技术在医师改良支架移植物构建中的安全性与有效性
本研究报道了采用非均匀约束和延迟释放缩径的医师改良支架移植物(PMEG)行开窗血管内主动脉修复(FEVAR)治疗复杂主动脉瘤的结果。203例患者中,靶血管插管和桥接支架输送成功率为100%,30天死亡率为2.5%,1年全因死亡率为7.8%,未发生开放转归。该技术允许序贯靶血管插管和支架输送,且不牺牲安全性和有效性。
要点
- 延迟释放缩径使PMEG贴合主动脉解剖,允许序贯靶血管插管。
- 203例复杂主动脉瘤患者中靶血管插管和桥接支架输送成功率达100%。
- 30天死亡率2.5%,1年全因死亡率7.8%,无开放转归。
核心结论
- 延迟释放缩径使PMEG贴合主动脉解剖,允许序贯靶血管插管和支架输送,且不损害安全性和有效性。
研究设计与样本
- 单中心医师发起的研究性器械豁免试验(NCT06501872,IDE#G240122,含导入队列),2015至2025年纳入203例接受PMEG-FEVAR的复杂主动脉瘤患者。
- 患者平均年龄75.3岁,71%为男性,94%为白人;动脉瘤类型包括近肾(25%)、肾旁(42%)、IV型(13%)和II/III/V型胸腹主动脉瘤(20%)。
- 平均动脉瘤直径59.9 mm,靶血管包括腹腔干(83%)、肠系膜上动脉(98%)、右肾动脉(96%)和左肾动脉(94%)。
主要发现
- 靶血管插管和桥接支架输送在100%的血管中成功完成,无术中死亡。
- 30天安全性结局:死亡率为2.5%,穿刺部位并发症发生率为5.4%,无肢体缺血。
- 1年结局:截瘫0.9%,轻瘫1.8%,靶血管不稳定6.7%,动脉瘤相关再干预7.6%,全因死亡7.8%,动脉瘤相关死亡1.5%,无开放转归。
关键数值与推荐
- 使用Cook Zenith Alpha Thoracic支架(近端/远端组件/延伸段)进行改良,在脏器段后方用5-0铬制肠线缩径至比每个Z支架水平主动脉直径小1 mm。
- 术中完全释放支架后保持缩径缝线 intact,先插管第一靶血管并放置桥接支架,然后通过小口径对侧经皮腹股沟入路序贯插管各靶血管并逐一桥接。
- 缩径缝线保持 intact,预期在后续14天内溶解。
- 依据血管外科学会(SVS)规定的30天和1年复杂主动脉腔内修复安全性和有效性报告标准进行分析。
临床怎么用
- 该技术通过延迟释放缩径实现序贯靶血管插管和支架输送,避免多根导丝同时位于靶血管内。
- 允许使用更小的对侧鞘管入路,降低术中靶血管风险。
- 适用于不适合商业支架或开放手术的复杂主动脉瘤患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Physician-modified endografts (PMEGs) remain an option to treat complex aortic aneurysms with fenestrated endovascular aortic repair (FEVAR) if they are unsuitable for commercial endografts or open surgery. FEVAR traditionally involves uniform diameter reduction for graft alignment and target vessel cannulation, after which diameter reduction is released before the delivery of bridging stent grafts. We describe the results of an advanced PMEG design using nonuniform constraints to mold the graft to the inner shape of the visceral aorta with delayed-release diameter reduction. This method allows for sequential vessel cannulation and thus sequential stent graft delivery without the need to have all targets concurrently cannulated. METHODS: Patients were treated with PMEG-FEVAR under a physician-sponsored investigational device exemption trial (NCT06501872, IDE#G240122, including lead-in cohort) from 2015 to 2025 at one institution. Cook Zenith Alpha Thoracic endografts (proximal/distal components/extensions) were modified with reinforced fenestrations and diameter reduced posteriorly with 5-0 chromic suture at the perivisceral portion to just 1 mm smaller than the aortic diameter at each Z-stent level. Intraoperatively, grafts were aligned, unsheathed completely, and diameter reduction ties were left intact with the graft achieving near apposition of the aortic wall at each level. The first target vessel is cannulated, and a bridging stent graft is placed; the graft is then released from the delivery mechanism. Then, in a sequential fashion, target vessels were cannulated through each fenestration and bridged with a stent graft one at a time via small-bore contralateral percutaneous groin access. The diameter reduction sutures are left intact and expected to dissolve over the following 14 days. We analyzed Society for Vascular Surgery-prescribed 30-day and 1-year reporting standards on safety and effectiveness for complex aortic endografting. RESULTS: Inclusion criteria were met by 203 patients who underwent PMEG-FEVAR (mean age, 75.3 years; 71% male; 94% White) for juxtarenal (25%), pararenal (42%), extent IV (13%), or extent II/III/V (20%) thoracoabdominal aortic aneurysms. The mean aneurysm diameter was 59.9 mm and target vessels included celiac (83%), superior mesenteric (98%), right renal (96%), and left renal (94%) arteries. Target vessel cannulation and delivery of bridging stent grafts was achieved in 100% of vessels. There were no intraoperative deaths. Safety and effectiveness outcomes include a 30-day mortality rate of 2.5%, access site complication rate of 5.4%, and no limb ischemia; at 1 year, outcomes included 0.9% paraplegia, 1.8% paraparesis, 6.7% target vessel instability, 7.6% aneurysm-related reintervention, 7.8% all-cause mortality, 1.5% aneurysm-related mortality, and no open conversions. CONCLUSIONS: Delayed-release diameter reduction molds PMEGs to the aortic anatomy, which allows for sequential target vessel cannulation and stent graft delivery without compromising safety or effectiveness. This technique avoids multiple concurrent wires in target vessels, allowing for smaller contralateral sheath access and less risk to target vessels intraoperatively.
引用
- Suckow BD, Bellamkonda K, Facciponte D, et al. Safety and efficacy of delayed-release diameter reduction in constructing physician-modified endografts for complex aortic aneurysms. J Vasc Surg. 2026. PMID: 41748040. doi:10.1016/j.jvs.2026.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。